SCHEMBL22700178

SCHEMBL22700178

CCOP(=O)(OCC)OC[C@H]1O[C@H]2C(n3cnc4c(N)nc(Cl)nc43)C2(CO)C1O

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NT5E P21589 6/20 0.50
ADORA3 P0DMS8 4/20 0.50
P2RY1 P47900 6/20 0.49
P2RY11 Q96G91 4/20 0.49
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA4 P22748 1/20 0.47
CA9 Q16790 1/20 0.47
ADORA2A P29274 2/20 0.47
PNP P00491 1/20 0.44
LMNA P02545 1/20 0.44
TP53 P04637 1/20 0.44
HTT P42858 1/20 0.44
PDE4D Q08499 1/20 0.44
PDE3A Q14432 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
ADORA2B P29275 1/20 0.44
ADORA1 P30542 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19979033 0.92 NT5E (0.51) NT5EADORA3P2RY1P2RY11CA1
SCHEMBL19979257 0.91 NT5E (0.49) NT5EADORA3P2RY1P2RY11CA1
SCHEMBL19978906 0.89 ADORA3 (0.42) NT5EADORA3P2RY1P2RY11ADORA2A
SCHEMBL22700179 0.88 NT5E (0.43) NT5EADORA3P2RY1P2RY11CA1
SCHEMBL22700164 0.86 PDE2A (0.52) NT5EADORA3P2RY1P2RY11
SCHEMBL19979029 0.84 ADORA2A (0.57) NT5EADORA3P2RY1P2RY11CA1
SCHEMBL19974418 0.84 ADORA2A (0.57) NT5EADORA3P2RY1P2RY11CA1
SCHEMBL22700160 0.83 ADORA2A (0.63) NT5EADORA3CA1CA2CA4
SCHEMBL22700177 0.80 NT5E (0.39) NT5EADORA3P2RY1P2RY11
SCHEMBL19978965 0.79 NT5E (0.44) NT5EADORA3P2RY1P2RY11CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3512860-B1 NUCLEOSIDE AND NUCLEOTIDE ANALOGUES BEARING A QUATERNARY ALL-CARBON STEREOGENIC CENTER AT THE 2' POSITION AND METHODS OF USE AS A CARDIOPROTECTIVE AGENT LCB PHARMA INC (CA) 2020-11-25 EP disclosed